Loading clinical trials...
Loading clinical trials...
Evaluation of Safety and Efficacy Evaluation Post Intravenous Infusion of Activated NK Cells in Recurrent and Refractory High-risk Neuroblastoma Patients
Conditions
Interventions
Allogenic NK cells infusion
Locations
1
Iran
Rasoul Akram Hospital
Tehran, Iran
Start Date
November 10, 2024
Primary Completion Date
November 1, 2026
Completion Date
November 1, 2026
Last Updated
April 9, 2025
NCT03189706
NCT04842526
NCT02748135
Lead Sponsor
Marzieh Ebrahimi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions